Skip to main content
Premium Trial:

Request an Annual Quote

Covance, RBM Ink Biomarker Services Pact

NEW YORK (GenomeWeb News) – Drug developer Covance and Rules-Based Medicine have struck a biomarker alliance and services agreement, Covance said today.

Under the pact, RBM will serve as Covance's exclusive third-party provider of multiplexed biomarker testing services, and Covance will serve as RBM's exclusive referral source for lab testing services.

The RBM Multi-Analyte Profiling platform creates efficiency in drug development by providing reproducible, quantitative, multiplexed immunoassay data for hundreds of proteins from small sample volumes, the company said.

"RBM's unique biomarker technology platform, combined with Covance's recent acquisitions and alliances in biomarkers and genomics, strengthens our ability to provide comprehensive biomarker discovery, verification, validation, and deployment in both the preclinical and clinical setting," Covance's Senior VP and President of Central Laboratory Services, Deborah Tanner, said in a statement.

The Scan

And Back

The New York Times reports that missing SARS-CoV-2 genome sequences are back in a different database.

Lacks Family Hires Attorney

A lawyer for the family of Henrietta Lacks plans to seek compensation from pharmaceutical companies that have used her cancer cells in product development, the Baltimore Sun reports.

For the Unknown

The Associated Press reports that family members are calling on the US military to use new DNA analysis techniques to identify unknown sailors and Marines who were on the USS Arizona.

PLOS Papers on Congenital Heart Disease, COVID-19 Infection Host MicroRNAs, Multiple Malformation Mutations

In PLOS this week: new genes linked to congenital heart disease, microRNAs with altered expression in COVID-19, and more.